Merus NV (FRA:2GH)
€ 48.4 -0.4 (-0.82%) Market Cap: 3.34 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 57/100

Merus NV at Citi Virtual Oncology Leadership Summit Transcript

Feb 23, 2023 / 03:00PM GMT
Release Date Price: €17.1 (+1.79%)
Yigal Nochomovitz
Citi - Analyst

Okay, awesome. This is Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. This is the third and final day of our Virtual Oncology Leadership Summit. And we're starting off the day with Bill Lundberg, he's the CEO of Merus. Bill, welcome. Thank you so much for taking the time to chat with us for an hour.

I think a lot of people obviously are very familiar with you guys and what you're doing. But nonetheless, it would be helpful to level set and maybe just give a quick two to three minute overview of the pipeline. Perhaps mention just some of the key catalysts coming up and maybe a word or two, just on how your technology platform is different from some of your peers developing bispecifics. Thanks.

Bill Lundberg
Merus NV - President, CEO & Principal Financial Officer, Executive Director

Thank you, Yigal. Thanks to the entire Citi team and thanks for the opportunity to speak and the continued support you provided Merus. This is a really exciting time for our company. We're an oncology-focused company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot